Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been confirmed to have one of these inherited cancer risk conditions: Hereditary Breast and Ovarian Cancer (HBOC), Lynch Syndrome, Neurofibromatosis Type 1, Li-Fraumeni Syndrome, PALB2-related cancer risk, or Hereditary Diffuse Gastric Cancer — either through genetic testing that found a relevant gene change, or through genetic testing that did not find a clear result but where the family history strongly suggests one of these conditions.
- People who are already receiving regular medical check-ups or cancer monitoring through a provincial screening program or surveillance protocol managed by a doctor.
- People who have signed and dated a consent form agreeing to take part in this study.
Who may not be able to join:
- People who have had a personal cancer diagnosis that was treated within the last 3 years before the study's first blood collection date — treatment must have been fully completed at least 3 years before that date.
- People who were diagnosed with cancer more than 3 years ago but never received treatment for it.
- People who are currently being investigated because a doctor suspects they may have cancer.
- People who would not be able to follow the study requirements, such as providing blood samples three times a year if placed in the experimental group.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Raymond Kim, MD, Princess Margaret Cancer Centre
Phone: 416-409-1387
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Determine the cancer detection rate of the cfDNA sequencing assay in patients with HCS.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.